Trial Profile
Single-center, Double-blind, Placebo-controlled, Randomized, Parallel-group, Up-titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Increasing Doses of ACT-128800 in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponesimod (Primary)
- Indications Graft-versus-host disease; Immunological disorders; Multiple sclerosis; Plaque psoriasis
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 13 Jan 2014 New source identified and integrated (ClinicalTrials.gov, NCT02029482)
- 19 Sep 2013 New trial record
- 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.